BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27774847)

  • 1. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
    DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
    Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
    Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
    Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
    Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
    Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
    Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
    Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
    PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demethylating agents in myeloid malignancies.
    Garcia-Manero G
    Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
    Jabbour E; Garcia-Manero G; Cornelison AM; Cortes JE; Ravandi F; Daver N; Kadia T; Teng A; Kantarjian H
    Leuk Lymphoma; 2015 Feb; 56(2):390-4. PubMed ID: 24844364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
    Gill H
    Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
    Gurion R; Vidal L; Gafter-Gvili A; Belnik Y; Yeshurun M; Raanani P; Shpilberg O
    Haematologica; 2010 Feb; 95(2):303-10. PubMed ID: 19773261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
    Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
    Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
    Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
    Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
    Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
    Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
    Sasaki K; Jabbour E; Montalban-Bravo G; Darbaniyan F; Do KA; Class C; Short NJ; Kanagal-Shamana R; Kadia T; Borthakur G; Pemmaraju N; Cortes J; Ravandi F; Alvarado Y; Chien K; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Soltysiak K; Yang H; Kantarjian HM; Garcia-Manero G
    NEJM Evid; 2022 Oct; 1(10):EVIDoa2200034. PubMed ID: 38319837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.
    Garcia JS; Jain N; Godley LA
    Onco Targets Ther; 2010 Jun; 3():1-13. PubMed ID: 20616953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target.
    Wang YH; Lin CC; Gurashi K; Wingelhofer B; Amaral FMR; Yao CY; Hsieh HT; Liu MC; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
    Leukemia; 2023 Dec; 37(12):2507-2511. PubMed ID: 37919605
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine.
    Takada E; Nakamura N; Kaneda Y; Fukuno K; Lee S; Fujita K; Morishita T; Ikoma Y; Matsumoto T; Nakamura H; Kitagawa J; Kanemura N; Kasahara S; Hara T; Tsurumi H; Shimizu M
    Hematol Rep; 2024 Feb; 16(1):114-124. PubMed ID: 38534882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.